TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: change in expression of glucose transporter type 4 (GLUT-4) in adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Migraine-like attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: suppression of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients That Have Achieved Complete Remission of Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in uptake of shared decision-making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of pressure ulcers at the sacrum
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of pressure ulcers at the heel
Endpoint domain: Adverse events/effects
Primary endpoint: 24-h Free-Living Glycemic Control Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in morning blood pressure (systolic and diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of CR+nCR to induction treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Doxapram-induced Panic Attack
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of the Doxapram-induced Panic Attack
Endpoint domain: Adverse events/effects
Primary endpoint: discharge time (voiding time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurodevelopment - Bayley
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in treatment outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst Grade of Adverse Event Experienced
Endpoint domain: Adverse events/effects
Primary endpoint: Clarity of cannula and VAD site demonstration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in insula anterior cingulate cortex signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Leg Pain or Lower Extremity Neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visualization of the main pancreatic duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in mucosal healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in erythrocyte sedimentation rate (SED rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fecal calprotectin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in C reactive protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HSCT Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percentual increase in forearm blood flow ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post Stress-Delta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-hour Stress-Delta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retina Vessel Density (RVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in comorbid conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical feasibility of PET-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of CMV infection
Endpoint domain: Adverse events/effects
Primary endpoint: Average time of daily physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients without nephrotic syndrome recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: bucco-palatal tipping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Abiraterone Acetate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Greater Than or Equal to 50 Percent Decline in Prostate Specific Antigen (PSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of successful procedures with evaluable CLE-imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Detection rate of gastric intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bone quality markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Positive IVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Retinal nerve fiber layer thickness measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rate of true recurrent pterygium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity assessed by NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leukocytosis level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: prevalence of vascular cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Patient-Reported Symptom Burden (Edmonton Symptom Assessment System)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient-Reported Symptom Burden (NCCN Distress Screening Tool)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients cured
Endpoint domain: Mortality/survival
Primary endpoint: Validity of the Growth Hormone Compliance Questionnaire child/adolescent version (GHCQ-CA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Validity of the Growth Hormone Compliance Questionnaire parent version (GHCQ-P)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bias and precision of creatinine measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ultrasonography record (synovitis / tenosynovitis / effusion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical joint assessment (synovitis / tenosynovitis / effusion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Evaluate SELENA SLEDAI (C-SLEDAI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluate musculoskeletal BILAG score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: decreased frequency of micturitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: no urgency noted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: less than 3 wakening at bedtime for micturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage agreement between novel biomarker measurements and existing scores of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Nutritional Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Psychosocial Status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Young's modulus (kPa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pathological Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Change From Baseline in Vaginal Dilator Induced Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity - Steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity - Minutes of Moderate or Vigorous Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total consumption of disinfectants per visitor
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of participants with a concentration of hemoglobin less than 11g/dL after delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of participants tested positive for malaria
Endpoint domain: Adverse events/effects
Primary endpoint: Change scores of Montreal Cognitive Assessment (MoCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change scores of the Disability Assessment for Dementia (DAD)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change scores of the Quality of Life in Alzheimer's Disease Instrument (QoLAD)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Ataxia rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in spatiotemporal gait measures using objective gait analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in upper limb co-ordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Network fragmentation using Quantitative EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total EPO Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent (%) of Hb Measurements After Implantation Within 9-11 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent (%) of Hb Measurements After Implantation Within 9-12 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivery Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cmax after oral administration of PXS-5382A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax after oral administration of PXS-5382A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of PXS-5382A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of PXS-5382A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant adherence to monitoring pre-TAVI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Timeliness of medical assessment of participants with serious arrhythmia identified on monitor pre-TAVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative number of observed AKs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AUC0-tz of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy for diagnosis of non-Hodgkin lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy for diagnosis of invasive breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood sodium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infectious complications at D30 postoperative
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Eastern Cooperative Oncology Group (ECOG) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levator function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical relapse prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain functional interference index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: cumulated incidence of nosocomial pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: number of ventilatory free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence risk of symptomatic P. vivax malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in severity and frequency of auditory verbal hallucinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of subtherapeutic antibiotic concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival with Unassisted Breathing
Endpoint domain: Mortality/survival
Primary endpoint: Dynamic changes in SDF-1α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma Concentration of Sugammadex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Carotid-femoral Pulse Wave Velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Half-life time of nevirapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Progress-free-survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in plasma bile acid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: EPR signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial colony forming units (CFUs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients with WHO grade ≥ 2 bleeding complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Specificity of vibro-acoustography imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Modification of the Composition of the Intestinal Microflora: Bifidobacterium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Modification of the Composition of the Intestinal Microflora: Clostridium Perfringens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Modified Prognostic Inflammatory and Nutritional Index (PINI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: quantitative change in CIMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and severity of GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gut maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific proteins in stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tender Point Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Diagnostic performance of PD-L1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Seroprotection Rate of Type 2 Polio Neutralizing Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of active tuberculosis
Endpoint domain: Adverse events/effects
Primary endpoint: Stroke recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Diagnostic Accuracy of rHVPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With Remission of Solar Urticaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AUC and Cmax of active metabolite of artesunate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 9-month Target Lesion Failure (TLF) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic sensitivity of the HINTS test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic specificity of the HINTS test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term disability status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of achieving minimal clinically significant change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients with disappearance of all symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving targeted mean reduction in global risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood metabolic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration-time curve from time 0 to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration-time curve (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serial FEV1-time Curve (AUC 0-12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1 Trough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cure for Parkinson's Disease
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with positive SRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: congruence between prostate cancer testing intention and behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge about prostate cancer and prostate cancer tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Verified doctor visit to discuss prostate cancer testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Symptomatic improvement of BPH symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of Dry Eye Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: University of Michigan Sedation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event Free Survival rate (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: Interval to first PCIA bolus injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient comfort (EDIN score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Insulin secretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Recovery from Early Neonatal Sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline in Asthma Control Test score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nutritional and physiological status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: toxicity (detection of replication competent retrovirus)
Endpoint domain: Adverse events/effects
Primary endpoint: ocular discomfort scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival 1 (PFS1)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Achieving PASI-75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in the measurement of blood biomarker levodopa (ng/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the measurement of blood biomarker glucagon-like peptide-1 (GLP-1) (pm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the measurement of blood targeted short chain fatty acids (SCFA) metabolomics concentrations (ug/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Successfully Transitioned
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast enhancement in echography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal intensity of enhancement peak in echography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean transit time of enhancement in echography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak exercise minute ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Progression-free Survival at 2 Years
Endpoint domain: Mortality/survival